To explore the capability of the CD44-targeted nanoagent DXBTZ-CB[8]/CSA to detect tumors by means of multispectral optoacoustic imaging, we first established a mouse model of subcutaneous tumor by injecting MDA-MB-231 cells onto the back of mice. This evidence concerns the gene CD44 and neoplasm.